Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 4 EP applications Margaretha Olthoff has served for within the last five+ years. (We consider all applications which have an EP A1 publication dated after February 18, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP11727396

ORAL DOSAGE FORMS OF BENDAMUSTINE

IPC classification:
A61K 9/14, A61K 9/48, A61K 31/4184, A61K 47/10
Agent:
Margaretha Olthoff, Astellas Pharma Europe BV
Status:
EXAMINATION IN PROGRESS
EP11727917

ORAL DOSAGE FORMS OF BENDAMUSTINE AND THERAPEUTIC USE THEREOF

IPC classification:
A61K 9/14, A61K 9/16, A61K 9/20, A61K 9/28, A61K 9/48, A61K 31/4184, A61K 47/10
Agent:
Margaretha Olthoff, Astellas Pharma Europe BV
Status:
EXAMINATION IN PROGRESS
EP14701907

COMPOSITION OF TIACUMICIN COMPOUNDS

IPC classification:
A61K 9/00, A61K 9/16, A61K 47/36, A61K 47/38
Agent:
Margaretha Olthoff, Astellas Pharma Europe BV
Status:
GRANT OF PATENT INTENDED
EP16075001

SYSTEM AND METHOD FOR ANALYZING ADVERSE EVENT DATA

IPC classification:
G06F 19/00
Agent:
Margaretha Olthoff, Astellas Pharma Europe BV
Status:
Request for examination was made

Please Sign in to use this feature